In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Rising Leaders Companies Business Strategies

Taking A Bold Path To Improve Fibrosis Prognosis

Agomab Is Targeting Two Growth Factor Pathways Which Could Help To Modify Disease Outcomes

  • Interviews

Executive Summary

Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.

You may also be interested in...



BioFactura Completes Phase I For Late-To-Market Stelara Biosimilar

BioFactura has completed a successful Phase I trial of its Stelara (ustekinumab) biosimilar BFI-751, which is expected to file in developed markets in 2026.

Generics Industry Preps For Potential Entry Of Ukraine Into EU

Generics industry trade group Medicines for Europe has met with Ukrainian government officials to discuss how to plan for any future integration process.

Adcock Remains Resilient In Tough Business Environment

Adcock saw its profits grow by 4.2% during FY 2024 despite a challenging economic environment.

Table

View full table

Topics

Related Companies

Tags:
Rising Leaders Companies Business Strategies
Latest Headlines

Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition

AI Medical Imaging And Radiotherapy First For UK’s NICE

The Power Of AI To Map The Patient Journey

A Next-Gen Approach To Health Care Risk And Compliance

See All
UsernamePublicRestriction

Register

IV146736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By